Recurrence of Type 2 MPGN Significantly Reduce Graft Surviva

A recent reports on the Membrano-proliferative Glomerulonephritis(MPGN) have shown that the recurrence of this disease would significantly reduce the graft survival rate in the patients. What’ the matter? Take for a thorough look.
Nowadays many patients with end stage renal disease(ESRD) caused by lots of diseases including Membrano-proliferative Glomerulonephritis(MPGN) have been accepting the kidney graft. However, not all the patients enjoy a comfortable life after their kidney graft.
Here I want to say the renal graft related with Membrano-proliferative Glomerulonephritis(MPGN). Membrano-proliferative Glomerulonephritis(MPGN)is a kind of the diseases of glomerulonephritis(GN). GN is the most rare primary disease among the various diseases which lead to ESRD. Some glomerular diseases will be recurrent after the kidney graft, for example, Membrano-proliferative Glomerulonephritis(MPGN), IgA Nephropathy, and focal segmental glomerulosclerosis(FSGS), etc.What Treatments Are Available for Mesangial Proliferative Glomerulonephritis
So for these patients with Membrano-proliferative Glomerulonephritis(MPGN), if they want to accept the graft operation, they should keep their disease stable for over half years and then, they can consider the kidney graft.
For the Type 2 Membrano-proliferative Glomerulonephritis(MPGN) patients who accepted the graft, their recurrence rate for the MPGN is as high as 90 percent, and their chances of suffering Kidney Failure after transplant is about 20 to 50 percent.Prednisones to Patients with Mesangial Proliferative Glomerulonephritis
Type 2 Membrano-proliferative Glomerulonephritis(MPGN) is an uncommon form of complement-dependent acquired renal disease, although it is rare, most patients who acquire this are easily progressing in to the ESRD, so more than half these patients have to receive renal graft therapy.End Stage Renal Disease Secondary to Chronic Glomerulonephritis
So experts remind that the renal transplant in the patients with Type 2 Membrano-proliferative Glomerulonephritis(MPGN) should be undertaken with caution, and these patients should be told in advance the poor overall graft survival conditions.

Considering this dilemma situation, we hospitals have proposed the newest Stem cell therapy for Type 2 Membrano-proliferative Glomerulonephritis(MPGN). This is an overall and brand-new technology, and it can help the patients prevent the outcome of renal graft. If you want to know this knowledge, consult us for more.